U.S. Tobacco Stock News

Recently, Ardagh Metal Packaging reported past-year revenue growth of 18.61% and a net profit increase of 54.55%, achieving a financial score of 7.74 that ranks 9 out of 22 in the Containers & Packaging industry. Despite this earnings momentum, the company is still assessed as financially weak with only average operating efficiency, underscoring a gap between improving results and overall financial strength. We will now explore how this stronger revenue and profit performance may influence...

AI Infrastructure Stocks sit at the crossroads of two powerful forces: real world capacity building and the long term adoption of artificial intelligence. While inflation trends, central bank policy and energy markets keep shifting, one constant is the heavy demand for data centers, power, cooling and connectivity that makes AI possible. This screener focuses on companies that turn that demand into actual cash flow, not just headlines. In this article you will see 3 of the best stocks from...

Atlantis Casino Resort Spa’s 2025 “Once Is All It Takes” brand campaign has received national honors from the Hermes Creative Awards and Viddy Awards, prompting fresh attention on Monarch Casino & Resort (MCRI) stock. See our latest analysis for Monarch Casino & Resort. The awards attention arrives as Monarch Casino & Resort’s share price trades at $130.66, with a 30-day share price return of 11.86% and a 36.05% year-to-date share price return. The 1-year total shareholder return of 55.71%...

In recent months, Universal Corp has seen institutional ownership rise to 95.24% of shares, alongside higher revenue and a very large jump in net profit, underscoring strong operational efficiency and financial health relative to Food & Tobacco peers. At the same time, the stock’s technical picture has turned bearish despite this robust institutional backing, highlighting an unusual disconnect between trading signals and the company’s improving fundamentals. We’ll now examine how stronger...

Deluxe (DLX) has drawn fresh investor attention after recent share price weakness, with the stock down about 3% over the past month and about 16% over the past 3 months. See our latest analysis for Deluxe. At a share price of $22.94, Deluxe has given investors a 3.38% year to date share price return. The 1 year total shareholder return of 63.73% and 3 year total shareholder return of 70.23% point to earlier momentum that contrasts with the recent 90 day share price decline of 15.88%. If you...

Albemarle (ALB) has drawn fresh attention after recent share price weakness, with the stock down 6% over the past month and 4% over the past 3 months. This has prompted investors to reassess its valuation and business mix. See our latest analysis for Albemarle. Beyond the recent weakness, Albemarle’s 1 day share price return of down 3.73% and 7 day return of down 5.91% sit against a year to date share price gain of 11.41%. The 1 year total shareholder return of about 1.9x contrasts with...

What Hubbell's Recent Performance Tells Investors Hubbell (HUBB) has caught investor attention after a period of steady share price gains, with the stock recently closing at $523.69 and posting double digit total returns over the past year and past 3 months. See our latest analysis for Hubbell. Recent trading has added to Hubbell's positive trend, with a 2.91% 1 day share price return and a 10.25% 30 day share price return, alongside a 33.91% 1 year total shareholder return that points to...

Analyst upgrade puts Kanzhun in focus Bernstein’s upgrade of Kanzhun (NasdaqGS:BZ) following its Q1 2026 results has put the stock back on many investors’ radars, with attention on revenue trends, user metrics, and AI driven matching. See our latest analysis for Kanzhun. The upgrade lands after a mixed stretch for Kanzhun, with the share price up 2.62% over 90 days but down 34.48% year to date and the 1 year total shareholder return declining 22.64%. This suggests recent momentum is tentative...

Generac Holdings (GNRC) is stepping up its manufacturing expansion with a new Belvidere, Illinois facility aimed at increasing packaging capacity for large megawatt generators as institutional ownership and earnings expectations draw fresh attention to the stock. See our latest analysis for Generac Holdings. The recent Belvidere expansion comes as Generac Holdings trades at US$279.15, with a 90-day share price return of 38.30% and a 1-year total shareholder return of 119.22%. These figures...

Analyst commentary has recently highlighted Newmark Group (NMRK) as undervalued relative to peers, pointing to supportive valuation metrics and a favorable earnings outlook that together are drawing fresh attention to the stock. See our latest analysis for Newmark Group. Recent trading has been relatively steady, with Newmark Group's share price at $14.87 and a 90-day share price return of 2.20%. Its 1-year total shareholder return of 34.52% reflects momentum that has built over a longer...

SNAP restrictions on sugary and highly processed foods are putting fresh attention on health and wellness food stocks, as billions in assisted grocery spending are reconsidered. For investors, this kind of policy shift can change which companies benefit from consumer demand tied to assistance programs and which feel pressure on sales of less nutritious products. This article looks at 3 stocks from a Health and Wellness Food Companies screener that appear more aligned with cleaner labels and...

BioLife Solutions (BLFS) is back in focus after Prosper Stars & Stripes added the stock to its portfolio again, pointing to the company’s renewed emphasis on core biopreservation media as well as cell and gene therapy exposure. See our latest analysis for BioLife Solutions. Recent trading reflects that shift in attention, with BioLife Solutions showing a 35.84% 90 day share price return and a 22.71% 1 year total shareholder return, while the current share price sits at $26.04 as investors...

Cytokinetics has entered a new phase as a commercial-stage biotech after securing FDA and European Commission approvals for Myqorzo, its first marketed therapy for symptomatic obstructive hypertrophic cardiomyopathy, and beginning its U.S. launch. An important implication is that Cytokinetics now shifts from being purely development-focused to also managing real-world product uptake, reimbursement, and regional rollouts, which can materially reshape its operating profile and risk mix. With...

Skyworks Solutions (SWKS) is back in focus after quarterly revenue and EPS both beat analyst estimates, with CEO Phil Brace pointing to solid execution and improving momentum across the company’s product portfolio as key drivers. See our latest analysis for Skyworks Solutions. At a share price of $72.45, Skyworks Solutions has seen a 32.96% 90 day share price return and a 12.51% year to date share price return, while the 5 year total shareholder return is down 53.17%. This suggests that...

Argan (AGX) is back on investors’ radar after record first quarter fiscal 2027 results highlighted revenue and earnings growth from energy infrastructure projects, along with a fresh quarterly dividend declaration that underscores ongoing shareholder return plans. See our latest analysis for Argan. The latest quarterly update and dividend news arrive alongside a sharp shift in market sentiment, with Argan’s 90 day share price return of 59.53% and year to date share price return of 126.67%...

AI is no longer just a story about experiments and cash burn; it is increasingly about companies that turn heavy AI investment into real earnings. With inflation, rates, and energy prices all in focus, many investors are looking for businesses that already know how to convert AI spending into profits instead of promises. The Profitable AI Stocks screener is built for this, highlighting companies that are not only serious about AI but are also earning from it. In this article, you will see 3...

With inflation trends and central bank policies pulling markets in different directions, many investors are looking for a steadier source of portfolio income. That is where high yield dividend stocks come in. The Dividend Powerhouses screener focuses on companies with yields above 5% that are described as well covered, growing and stable, offering a rules based way to focus on income payers rather than chasing headlines. In this article, you will see three stocks from this screener that stand...

Clinical PSMA Data Sparks Fresh Look At Vir Biotechnology Stock Vir Biotechnology (VIR) has moved back onto investors' radars after new PSMA clinical data in prostate cancer prompted an updated investment thesis and renewed focus on the company’s T cell engager pipeline. See our latest analysis for Vir Biotechnology. At a share price of US$9.16, Vir Biotechnology’s short term picture reflects a mix of optimism and caution, with a 7 day share price return of 6.39% and a year to date share...

Starwood Property Trust, Inc. previously declared a quarterly dividend of US$0.48 per common share for the period ended June 30, 2026, payable on July 15, 2026 to shareholders of record as of June 30, 2026. While this payout supports the company's income-oriented profile, its very large payout ratio versus earnings raises questions about how comfortably future dividends can be supported. Next, we’ll examine how this US$0.48 dividend declaration, and the questions around its coverage,...

Recently, Hilton Worldwide Holdings reported double-digit year-over-year growth in both revenue and net profit and continued to be recognized for its solid financial position within the Hotels & Entertainment Services industry, while institutional investors increased their aggregate holdings to slightly above the company’s total free float. At the same time, institutional ownership reached the highest score in its industry and Hilton launched a large-scale mentorship and travel-points...

Synovis Micro Companies Alliance, a subsidiary of Baxter International (BAX), has signed an exclusive multi-year deal with MediThinQ to distribute the SHIYA 3D surgical visualization platform globally, expanding Baxter’s footprint in digital surgical technology. See our latest analysis for Baxter International. The MediThinQ agreement arrives after a volatile stretch for Baxter International, with a 19.75% 90 day share price return contrasting with a 33.11% decline in 1 year total shareholder...

Acuity is approaching its Q3 earnings release, with analysts previously expecting a slight year-on-year earnings-per-share increase and modest overall revenue growth, driven by differing trajectories across its segments. Expectations that Acuity Intelligent Spaces could grow meaningfully while Acuity Brands Lighting contracts highlight how the company’s mix shift may influence investor focus and risk assessments. We’ll now explore how the anticipated strength in Acuity Intelligent Spaces,...

SEI Investments (NasdaqGS:SEIC) has created new executive roles to scale its AI and data strategy across the enterprise. The company appointed Matt Provencher as Global Head of Enterprise Professional Services to lead its expanded services organization. SEI is rolling out next generation platforms, AI powered tools, and enterprise wide automation initiatives to support clients. SEI Investments operates at the intersection of technology and investment services, providing platforms and...

Kymera Therapeutics (KYMR) is back in focus after sharing new data on its protein degrader pipeline, including Phase 1 results for KT-621 in healthy Japanese adults and expanded preclinical findings for lupus candidate KT-579. See our latest analysis for Kymera Therapeutics. Kymera Therapeutics’ recent KT-621 and KT-579 readouts arrive after a period of strong momentum, with the latest share price at $90.43, a 30 day share price return of 14.63% and a one year total shareholder return of...